SCHEMBL5320715

SCHEMBL5320715

CC1CN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)c1cccs1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCKR Q14397 2/20 0.52
PKM P14618 3/20 0.48
MMP1 P03956 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
MMP9 P14780 1/20 0.45
LMNA P02545 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
SETD7 Q8WTS6 1/20 0.42
GPR119 Q8TDV5 3/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383019 0.88 MMP1 (0.49) GCKRPKMMMP1MMP3MMP7
SCHEMBL27727372 0.81 MMP1 (0.56) MMP1MMP3MMP7MMP9MEN1
SCHEMBL16781 0.81 PKM (0.71) PKMMAPTKMT2AALDH1A1POLB
SCHEMBL5322126 0.80 GCKR (0.51) GCKRPKMMMP1MMP3MMP7
SCHEMBL15919223 0.79 MMP1 (0.48) MMP1MMP3MMP7MMP9SETD7
SCHEMBL15919201 0.79 MMP1 (0.48) MMP1MMP3MMP7MMP9SETD7
SCHEMBL15919202 0.79 MMP1 (0.48) MMP1MMP3MMP7MMP9SETD7
SCHEMBL309055 0.78 MMP1 (0.55) MMP1MMP3MMP7MMP9MAPT
SCHEMBL31471875 0.78 HSD11B1 (0.52) GCKRPKMMEN1KMT2AGPR119
SCHEMBL309795 0.78 MMP1 (0.55) MMP1MMP3MMP7MMP9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US claimed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
US-20070259879-A1 Piperazine and piperidine biaryl derivatives TRIMERIS, INC. 2007-11-08 US disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 WO disclosed
WO-2007103456-A2 PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES TRIMERIS, INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259879-A1 Piperazine and piperidine biaryl derivatives CYP3A5, CYP3A43, CCR5 GCKR 2871/4885PKM 1252/4885MMP1 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.